메뉴 건너뛰기
Journal of Clinical Oncology
Volumn 33, Issue 21, 2015, Pages 2405-2406
Cetuximab is contraindicated in the perioperative treatment of colorectal liver metastases

(14)  Primrose, John N a   Cunningham, David b   Garden, O James c   Maughan, Tim S d   Pugh, Siân A a   Stanton, Louise a   Falk, Stephen J e   Rees, Myrddin f   Finch Jones, Meg e   Valle, Juan W g   O'Reilly, Derek h   Hornbuckle, Joanne i   Hickish, Tamas j   Bridgewater, John A k  

Author keywords

[No Author keywords available]
Indexed keywords

CETUXIMAB; ANTINEOPLASTIC AGENT; RAS PROTEIN;
EID: 84940366697     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.60.1344     Document Type: Letter
Times cited : (5)
References (7)
  • 1
    • 84921764691 scopus 로고    scopus 로고
    • Should the results of the New EPOC trial change practice in the management of patients with resectable metastatic colorectal cancer confined to the liver?
    • Nordlinger B, Poston GJ, Goldberg RM: Should the results of the New EPOC trial change practice in the management of patients with resectable metastatic colorectal cancer confined to the liver? J Clin Oncol 33:241-243, 2014
    • (2014) J Clin Oncol , vol.33 , pp. 241-243
    • Nordlinger, B.1    Poston, G.J.2    Goldberg, R.M.3
  • 2
    • 84899900161 scopus 로고    scopus 로고
    • Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: The New EPOC randomised controlled trial
    • Primrose J, Falk S, Finch-Jones M, et al: Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: The New EPOC randomised controlled trial. Lancet Oncol 15:601-611, 2014
    • (2014) Lancet Oncol , vol.15 , pp. 601-611
    • Primrose, J.1    Falk, S.2    Finch-Jones, M.3
  • 3
    • 40749149728 scopus 로고    scopus 로고
    • Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): A randomised controlled trial
    • Nordlinger B, Sorbye H, Glimelius B, et al: Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): A randomised controlled trial. Lancet 371:1007-1016, 2008
    • (2008) Lancet , vol.371 , pp. 1007-1016
    • Nordlinger, B.1    Sorbye, H.2    Glimelius, B.3
  • 4
    • 84921815526 scopus 로고    scopus 로고
    • Patterns of progression, treatment of progressive disease, and postprogression survival in the new EPOC study
    • Pugh SA, Ball A, Bowers M, et al: Patterns of progression, treatment of progressive disease, and postprogression survival in the new EPOC study. J Clin Oncol 32:227s, 2014 (suppl; abstr 3556)
    • (2014) J Clin Oncol , vol.32 , pp. 227s
    • Pugh, S.A.1    Ball, A.2    Bowers, M.3
  • 5
    • 84921815526 scopus 로고    scopus 로고
    • Patterns of progression, treatment of progressive disease, and postprogression survival in the new EPOC study
    • Bridgewater JA, Pugh SA, Moutasim K, et al: Patterns of progression, treatment of progressive disease, and postprogression survival in the new EPOC study. J Clin Oncol 32:227s, 2014 (abstr 3556)
    • (2014) J Clin Oncol , vol.32 , pp. 227s
    • Bridgewater, J.A.1    Pugh, S.A.2    Moutasim, K.3
  • 6
    • 84940376613 scopus 로고    scopus 로고
    • Mir-31-3p as a predictive biomarker of cetuximab effects in a post hoc analysis of new EPOC phase III trial
    • Laurent-Puig P, Bridgewater JA, Primrose JN, et al: Mir-31-3p as a predictive biomarker of cetuximab effects in a post hoc analysis of new EPOC phase III trial. J Clin Oncol 32:218s, 2014 (suppl; abstr 3523)
    • (2014) J Clin Oncol , vol.32 , pp. 218s
    • Laurent-Puig, P.1    Bridgewater, J.A.2    Primrose, J.N.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.